Clinical Validation of Isothermal Nucleic Acid Amplification Bioassays Modules - GUINEA
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The FORTIFIEDx & DECIPHER projects aim to improve the diagnostic capacity for VHFs by developing two novel POC diagnostic tools capable of detecting EBOV and LASV. These tools are designed to enhance diagnostic sensitivity and specificity compared to existing rapid diagnostic solutions, thereby enabling faster and more accurate case detection. Improved diagnostic performance is expected to lead to better patient care and more effective outbreak control. Additionally, it aims to minimize healthcare worker's exposure to contaminated bodily fluids by supporting self-testing with healthcare worker assistance.
To validate the clinical performance of both the FORTIFIEDx and DECIPHER bioassays modules, two retrospective studies will be conducted using biobanked plasma samples and/ or buccal swabs from patients previously tested for EBOV and LASV. These samples, collected by the CRV-LFHVG, include both test-positive and test-negative cases confirmed by gold-standard RT-PCR assays. These studies are crucial steps in the evaluation of the FORTIFIEDx & DECIPHER diagnostic tools. Leveraging existing biobanked samples allows for the generation of clinically relevant performance data without the need for new patient recruitment.
The primary objective is to estimate the sensitivity and specificity of the bioassay modules for LASV and EBOV compared to standard RT-PCR on biobanked patient samples. As a secondary objective, the investigators will evaluate other endpoints related to diagnostic accuracy and concordance (e.g. positive and negative predictive values) and the inverstigators will evaluate the user-friendliness (by the laboratory technician) of the bioassay modules.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Koen Vercauteren, Prof. Dr.
- Numéro de téléphone: +32 3 247 63 32
- E-mail: kvercauteren@itg.be
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- EBOV and LASV test positive and negative biobanked patient samples
Exclusion Criteria:
- not applicable
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
LASV positives
|
FORTIFIEDx bioassay, using recombinase polymerase amplification for a qualitative readout and DECIPHER bioassay, using recombinase polymerase amplification for a quantitative readout
|
|
EBOV positives
|
FORTIFIEDx bioassay, using recombinase polymerase amplification for a qualitative readout and DECIPHER bioassay, using recombinase polymerase amplification for a quantitative readout
|
|
LASV and EBOV negatives
|
FORTIFIEDx bioassay, using recombinase polymerase amplification for a qualitative readout and DECIPHER bioassay, using recombinase polymerase amplification for a quantitative readout
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Assess sensitivity and specificity of the FORTIFIEDx and DECIPHER bioassays for EBOV and LASV
Délai: Up to 1 year after the intervention
|
The FORTIFIED assay gives qualitative results.
The DECIPHER assay gives quantitative results for EBOV and LASV, which will be classified as positive or negative.
It is assumed that a higher value indicates a higher viral load.
The threshold for each pathogen will be determined as follows: (1) the maximum threshold that achieves ≥80% sensitivity, (2) the minimum threshold that achieves ≥80% specificity, (3) the threshold that maximizes Youden's index and (4) the threshold that minimizes the Euclidean index.
Note that approach (1) and (2) will give an unbiased estimate of sensitivity and specificity at these pre-specified thresholds, while approach (3) and (4) is expected to overestimate sensitivity and specificity.
Sensitivity and specificity (together with their 95% Wilson CI) will be calculated using the observed number of true and false positives and negatives.
Positive and negative predictive value will be estimated using the calculated sensitivity and specificity.
|
Up to 1 year after the intervention
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Evaluate the usability of the bioassays by laboratory technicians - quantitative feedback
Délai: Up to 1 year after the intervention
|
Responses from the standardized questionnaire completed by laboratory technicians will be analysed using descriptive statistics.
Quantitative usability metrics (such as ease of use scores, time requirements, and satisfaction ratings) will be summarized using (cumulative) counts and percentages or using medians, quartiles and ranges as appropriate.
|
Up to 1 year after the intervention
|
|
Evaluate the usability of the bioassay by laboratory technicians - qualitative feedback
Délai: Up to 1 year after the intervention
|
Responses from the standardized questionnaire completed by laboratory technicians will be analysed using descriptive statistics.
Qualitative feedback regarding workflow integration, clarity of instructions, and implementation challenges will be categorized and analysed thematically to identify common patterns and areas for improvement in the bioassay system design and user interface.
|
Up to 1 year after the intervention
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Karifa Kourouma, MD, MSc, Centre National de Formation et de Recherche en Santé Rurale, Maferinyah, Guinea
- Chercheur principal: Alimou Camara, Dr., Centre de Recherche en Virologie, Laboratoire des Fièvres Hémorragiques Virales de Guinée, Conakry, Guinea
- Chercheur principal: Koen Vercauteren, Dr. Prof., Institute of Tropical Medicine, Antwerp, Belgium
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2020/26
- 101137242 (Autre subvention/numéro de financement: Horizon Europe)
- 101092049 (Autre subvention/numéro de financement: Horizon Europe)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .